What factors could boost MGRM's EPS in 2025?

**Monogram Technologies Inc. (MGRM) is poised to experience an EPS growth driven by several key factors in 2025.** Here's a detailed analysis: 1. **Commercialization of Surgical Robot**: Monogram is readying the commercialization of its next-generation surgical robot, the mBôs, which is strategically positioned to capitalize on the growing orthopedic surgery robotic market. The market for orthopedic surgery robots was valued at $6.8 billion as of 2022 and is expected to reach $16 billion by 2030, reflecting a compound annual growth rate (CAGR) of 13%. The company's robotic surgical equipment and related software are likely to contribute significantly to EPS growth as they gain market traction. 2. **FDA Clearances and Product Development**: Monogram has obtained FDA clearance for its mPress implants and is seeking clearance for its robotic products, which are crucial for market entry. The company's ongoing product development, including robotic surgical equipment, orthopedic implants, tissue ablation tools, and navigation consumables for reconstructive joint replacement procedures, are expected to bolster revenue and EPS growth. 3. **Financial Position and Strategic Initiatives**: Despite no product revenue and gross profit for the nine months ended September 30, 2024, Monogram has shown a decrease in operating expenses, which could lead to improved profitability as the company advances its products towards commercialization. The company's capital management and strategic initiatives, including the submission of a 510(k) premarket filing to the FDA, indicate a focused approach towards regulatory milestones and product scaling. 4. **Market Position and Growth Prospects**: Monogram's innovative product solution architecture and AI-driven robotics differentiate them in the market. The company's focus on patient-optimized orthopedic implants and its position as a leader in robotic surgery suggest a strong market demand for its products. As the company continues to innovate and commercialize its technologies, it is well-positioned for substantial revenue growth, which will directly impact EPS. In conclusion, Monogram Technologies Inc. is likely to see an EPS growth in 2025 driven by the commercialization of its surgical robot, FDA clearances, product development, strategic initiatives, and its strong market position. These factors collectively position Monogram for profitable long-term growth, supporting the potential for a positive EPS trajectory in the coming year.